Rules
How FDA and FTC rules shape cosmetic transformation timelines
How FDA and FTC rules shape cosmetic transformation timelines: banned ingredients, endorsement disclosure, and the evidence a clinic must hold.
What to take away
- The FDA decides which ingredients may legally sit in a cosmetic. The FTC decides what a marketer may claim about the result in a cosmetic transformation timeline.
- A timeline can satisfy one agency and fail the other.
- Mercury compounds, bithionol and unapproved color additives cannot appear in a US cosmetic.
- Paid celebrity posts must disclose the payment. Every result claim needs evidence on file.
- The FTC has sent penalty offense notices on substantiation and on endorsements to hundreds of companies.
Which ingredients cannot appear in a US cosmetic at all
The FDA publishes a short list of ingredients that are prohibited or restricted in US cosmetics. The authority behind that list is the Federal Food, Drug, and Cosmetic Act, and the prohibitions sit in 21 CFR Part 700. Check the list first when a timeline calls a product clean. The FDA's prohibited and restricted ingredients page is the outer boundary of any safety claim.
Mercury compounds are restricted to trace amounts in eye-area products. Bithionol, chloroform and methylene chloride are banned as intentional ingredients.
Color additives are the next trap. Each must be permitted for the exact use shown, so a pigment cleared for soap is not cleared for the eye area. The permitted uses are set out in the color additive regulations, 21 CFR Parts 70 through 82.
A numbing cream with lidocaine is a drug above certain strengths, not a cosmetic. Selling it as one mislabels the product, and that is an FDA matter.
The cosmetic and drug line falls on the claim. A product that promises to treat acne or prevent disease is a drug. The caption under a result image sets the category, so the same product can be a cosmetic in one post and a drug in the next.
FDA Cosmetic vs Drug Rules
Cosmetic
- FDA approval
- Not approved
- Lidocaine numbing
- Not cosmetic
- Color additives
- Exception
- Ingredient limits
- Restricted
Drug
- FDA approval
- Approved
- Lidocaine numbing
- Regulated as drug
- Color additives
- Approved
- Ingredient limits
- Strength-based
Where FDA authority ends and FTC advertising rules begin
The FDA polices ingredients and labeling. The FTC polices advertising, including a caption under a paid post.
FDA authority vs FTC rules
FDA
- Scope
- ingredients and labeling
- Premarket approval
- drugs, devices, color additives
- Typical first action
- warning letter, import alert
- Trigger
- prohibited ingredient or drug claim
FTC
- Scope
- advertising and endorsements
- Premarket approval
- none
- Typical first action
- warning letter, penalty notice
- Trigger
- unproven or misleading claim
The FTC's baseline rule is that advertising must be truthful, not misleading, and supported by evidence before it runs. That rule comes from Section 5 of the FTC Act, which bars unfair or deceptive acts or practices. The FTC's truth in advertising page states the principle.
Endorsement rules add a second layer. The FTC's Endorsement Guides, 16 CFR Part 255, treat payment or free treatment as a material connection that must be disclosed clearly.
Example: a six-month timeline read against both agencies
Take a singer who appears at an awards show with a visibly narrower nose, six months after a clinic consultation. Dates and lighting matter as much as the photograph. A documented procedures claim needs records, not captions.
Six-month timeline read
- "Nonsurgical nose job with an FDA approved filler." FDAfillers are drugs or devices, and clearance covers one specific use. FTC: the photos must support the cause.
- "Proprietary blend of natural ingredients." FDAnatural is not a legal category, and some botanicals are restricted. FTC: no reader can check a hidden list.
- "Photos show a 40 percent reduction in nose width." FTCa percentage needs matched lighting and measurement data.
- "Paid partnership with @clinic." FTCclear, prominent disclosure passes. Buried disclosure breaks the rule.
- "Results may vary." FTCa small line cannot rescue a headline promising the same result to everyone.
What a clinic must hold before it publishes a claim
Substantiation means the evidence exists before the claim goes live. For health claims the FTC expects competent and reliable scientific evidence, usually human data with a control group.
Eight items belong on file before publication:
- Signed consent forms that cover marketing use.
- Raw, unedited before and after images.
- Camera, lens, distance, lighting and angle for each shot.
- A measurement method another expert could repeat.
- Patient records showing what was actually done.
- The date of every photograph, tied to the procedure date.
- The published labeling for the product or device.
- The studies relied on, kept on file rather than summarized.
Substantiation Evidence Checklist
- Human studies, not animal
- Clinical trial with control group
- Standardized before and after photos
- Patient records and protocol
- Consent forms and raw photos
A veneers checklist applies the same audit to dental posts. The test is whether the clinic could hand the file to an investigator tomorrow.
What happens after a warning letter or a penalty offense notice
The FTC can issue a warning letter without going to court, and those letters are public. They usually ask the recipient to correct the claim.
Penalty offense notices carry more weight. In October 2021 the FTC sent notices about deceptive endorsements and reviews to more than 700 companies. In April 2023 it sent a notice about substantiation of product claims to more than 600 companies. Conduct named in a notice can draw civil penalties if it continues. The FTC keeps a public list of the covered practices.
The FDA sends warning letters too, often for drug claims or prohibited ingredients in the promoted product. A timeline that pushes such a product can draw attention from both agencies at once. An outside read helps, but a beauty expert analysis is opinion, not substantiation.
